UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Jiang T
(2023)
An empirical investigation into the impact of winner's curse on estimates from Mendelian randomization.
in International journal of epidemiology
Zembic A
(2021)
An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality.
in JAMA network open
Sanderson E
(2019)
An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings.
in International journal of epidemiology
Smith SM
(2021)
An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank.
in Nature neuroscience
Khaire AS
(2022)
An integrated genome and phenome-wide association study approach to understanding Alzheimer's disease predisposition.
in Neurobiology of aging
Zhou X
(2021)
An integrative analysis of genomic and exposomic data for complex traits and phenotypic prediction.
in Scientific reports
Olinger E
(2022)
An intermediate-effect size variant in UMOD confers risk for chronic kidney disease.
in Proceedings of the National Academy of Sciences of the United States of America
Li X
(2021)
An observational and Mendelian randomisation study on vitamin D and COVID-19 risk in UK Biobank.
in Scientific reports
Mountjoy E
(2021)
An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci.
in Nature genetics
Petermann-Rocha F
(2023)
An Opportunity for Prevention: Associations Between the Life's Essential 8 Score and Cardiovascular Incidence Using Prospective Data from UK Biobank.
in Current problems in cardiology
Ruzicka F
(2022)
An unbiased test reveals no enrichment of sexually antagonistic polymorphisms on the human X chromosome.
in Proceedings. Biological sciences
Sun Q
(2022)
Analyses of biomarker traits in diverse UK biobank participants identify associations missed by European-centric analysis strategies.
in Journal of human genetics
Ramírez J
(2021)
Analysing electrocardiographic traits and predicting cardiac risk in UK biobank.
in JRSM cardiovascular disease
Curtis D
(2022)
Analysis of 200 000 exome-sequenced UK Biobank subjects illustrates the contribution of rare genetic variants to hyperlipidaemia.
in Journal of medical genetics
Curtis D
(2021)
Analysis of 200,000 Exome-Sequenced UK Biobank Subjects Implicates Genes Involved in Increased and Decreased Risk of Hypertension.
in Pulse (Basel, Switzerland)
Curtis D
(2021)
Analysis of 50,000 exome-sequenced UK Biobank subjects fails to identify genes influencing probability of developing a mood disorder resulting in psychiatric referral.
in Journal of affective disorders
Schulz CA
(2023)
Analysis of associations between dietary patterns, genetic disposition, and cognitive function in data from UK Biobank.
in European journal of nutrition
Curtis D
(2020)
Analysis of exome-sequenced UK Biobank subjects implicates genes affecting risk of hyperlipidaemia.
in Molecular genetics and metabolism
Tkatchenko TV
(2019)
Analysis of genetic networks regulating refractive eye development in collaborative cross progenitor strain mice reveals new genes and pathways underlying human myopia.
in BMC medical genomics
Gao G
(2022)
Analysis of KIR gene variants in The Cancer Genome Atlas and UK Biobank using KIRCLE
in BMC Biology
Sorokin EP
(2022)
Analysis of MRI-derived spleen iron in the UK Biobank identifies genetic variation linked to iron homeostasis and hemolysis.
in American journal of human genetics
Emdin CA
(2018)
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease.
in Nature communications
Curtis D
(2022)
Analysis of rare coding variants in 200,000 exome-sequenced subjects reveals novel genetic risk factors for type 2 diabetes.
in Diabetes/metabolism research and reviews
Paik H
(2022)
Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort.
in PLoS computational biology
Grenn F
(2022)
Analysis of Y Chromosome Haplogroups in Parkinson's Disease
Grenn FP
(2022)
Analysis of Y chromosome haplogroups in Parkinson's disease.
in Brain communications
Deng WQ
(2019)
Analytical strategies to include the X-chromosome in variance heterogeneity analyses: Evidence for trait-specific polygenic variance structure.
in Genetic epidemiology
Hwang M
(2022)
Analyzing the Korean reference genome with meta-imputation increased the imputation accuracy and spectrum of rare variants in the Korean population
in Frontiers in Genetics
Slade GD
(2019)
Anatomical selectivity in overlap of chronic facial and bodily pain.
in Pain reports
Yin C
(2023)
Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment.
in Proceedings of the National Academy of Sciences of the United States of America
Lehrer S
(2023)
Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
in Anticancer research
Praveen K
(2022)
ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma.
in Communications biology
Ao Y
(2022)
Ankylosing Spondylitis and the Risk of Lung Cancer: A Meta-Analysis and Mendelian Randomization.
in Frontiers in genetics
Aung N
(2022)
Annotation and quality assessment of left ventricular filling and relaxation pattern using one-dimensional convolutional neural network
in European Heart Journal - Cardiovascular Imaging
O'Sullivan F
(2018)
Annual Ambient UVB at Wavelengths that Induce Vitamin D Synthesis is Associated with Reduced Esophageal and Gastric Cancer Risk: A Nested Case-Control Study.
in Photochemistry and photobiology
Tong TY
(2018)
Anthropometric and physiologic characteristics in white and British Indian vegetarians and nonvegetarians in the UK Biobank.
in The American journal of clinical nutrition
Chu P
(2022)
Antibodies to Human Herpesviruses and Rate of Incident Cardiovascular Events and All-Cause Mortality in the UK Biobank Infectious Disease Pilot Study.
in Open forum infectious diseases
Mur J
(2022)
Anticholinergic burden in middle and older age is associated with reduced cognitive function, but not with brain volume.
in International Journal of Population Data Science
Bansal N
(2022)
Antidepressant use and risk of adverse outcomes: population-based cohort study.
in BJPsych open
Chang HC
(2023)
Antidepressant use, chronic inflammatory comorbidities and behavioral disinhibition.
in Brain, behavior, and immunity
Chen J
(2023)
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.
in Alimentary pharmacology & therapeutics
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |